Results of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they ...

The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Please provide your email address to receive an email when new articles are posted on . The addition of post-transplant cyclophosphamide to sirolimus and cyclosporine reduced chronic GVHD. Efforts are ...

In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...

As part of consolidation therapy, patients may receive allogenic hematopoietic stem cell transplantation (HCT). HCT involves the replacement of a patient's normal source of bone marrow cells by ...

Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...

In preclinical studies, researchers found that priming the immune system with a Treg-expanding therapy before stem cell transplant boosted survival, protected vital organs, and promoted a balanced gut ...

Three-year data suggest improved overall survival with TREGZI™ versus post-transplant cyclophosphamide in patients with hematologic malignancies.

Faith Hinitt, 28, had to raise more than £100,000 after a second transplant was turned down.